The Global Market size of Acne Vulgaris (AV) was USD 5,360.1 Millions in 2013 and is expected to reach USD 14,226.3 Million by the end of 2023.
According to Industry Experts, the Diagnosed cases in 7 major markets for Acne Vulgaris (AV) were 113,959,366 cases in 2013 and are expected to be 136,929,289 cases in 2023.
Request Sample of this Report at: http://www.orbisresearch.com/contacts/request-sample/209395
Acne vulgaris is a common chronic skin disease/Disorder of pilosebaceous follicles. The disease is characterized by blockage and/or inflammation of hair follicles and their accompanying sebaceous gland. Acne develops in regions of high sebaceous gland. The disease is seen to occur mostly in adolescence. At puberty androgens due to the increase in sebum production from enlarged sebaceous glands, the glands become blocked. Propionibacterium acnes further colonise and lead to lesion production although its exact role is unclear.
“Acne Vulgaris (AV) Market Insights, Epidemiology and Market Forecast-2023” Report provides an overview of the disease and market size of the Acne Vulgaris for the global, United States, EU5 (France, Germany, Italy, Spain and United Kingdom) and Japan for 2013-2023. It also includes global historical and forecasted epidemiological data for the Acne Vulgaris Diagnosed Cases from 2013-2023.
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by Publisher team of industry experts.
Industry Scope in Report:
- Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2013-2023.
- It also provides Market size of Acne Vulgaris (AV) for United States, EU5 and Japan from 2013 and forecasted Market size to 2023.
Top Marketed Drugs for Acne Vulgaris
Acanya: Valeant Pharmaceuticals
Veltin: Almirall, S.A.
Epiduo and Epiduo Forte: Galderma S.A.
Sarecycline: Paratek Pharmaceuticals
Aczone reform: Allergan
SB204: Novan, Inc.
Check Discount on this Report Purchase at: http://www.orbisresearch.com/contacts/discount/209395
Orbis Research is a single point aid for all your Market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customised reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialisation. This helps our clients to map their needs and we produce the perfect required Market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
Email ID: email@example.com